compounded semaglutide with b12 + Injections Compounded Semaglutide + B12 -

Co-agonism of GLP-1 and GIP (as seen with the drug tirzepatide) results in greater weight loss and glucose control than GLP-1 alone

In type 2 diabetes trials, retatrutide showed greater improvements in body weight and HbA1c than reference GLP-1 receptor agonists such as dulaglutide

Semaglutide and tirzepatide are only approved for the treatment of a certain number of conditions: obesity and overweight, type 2 diabetes, sleep apnea, and cardiovascular disease

We became instant friends, and a year later here we are, together in the trenches, on the frontline of healthcare policy and patient advocacy

The increase in patients using GLP-1 drugs is in part because it is associated with weight loss in a world with increased pressure to lose weight due to beauty standards